Patients diagnosed with solid malignant tumors through histopathology or clinical diagnosis through enhanced CT, magnetic resonance imaging, etc
Conditions
Interventions
Experimental Group:ePRO-MAI Innovation Management
Control group:Routine management
Sponsors
Mianyang Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-75 years old; 2. Patients with solid malignant tumors confirmed by histopathology or clinical diagnosis such as enhanced CT or magnetic resonance imaging; 3. An expected survival time of at least 6 months; 4.Planned to receive >=4 cycles of day chemotherapy; 5. Be able and willing to fill out the electronic scale through mobile phone or tablet computer; 6. I am willing to undergo randomization and am able to comply with the planned visits, treatments, laboratory tests, and other trial procedures. I have provided written informed consent.
Exclusion criteria
Exclusion criteria: 1. Unable to understand the research content; 2. Received chemotherapy within one month before enrollment; 3. The patient is currently pregnant; 4. Participating in other clinical studies; 5. Severe mental illness or cognitive impairment; 6. Have other conditions that may increase the risk of participating in the study or interfere with the study results; 7. Other circumstances considered by the investigator to be inappropriate for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of changes in daytime treatment plan; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life;Karnofsky Performance Status;Incidence of adverse events and incidence of serious adverse events;Overall survival;Symptoms and functional load;Progression free survival (PFS)/disease-free survival (DFS);Incidence of unplanned medical treatment;Relative dose intensity; | — |
Countries
China
Contacts
Public ContactLi Jie
Mianyang Central Hospital
Outcome results
None listed